McKesson (NYSE:MCK) Sets New 52-Week High After Analyst Upgrade

Key Points

• McKesson shares reached a new 52-week high of $1,030.27 after Mizuho raised its price target from $905 to $1,020, though it maintained a neutral rating.
• Analyst sentiment remains broadly positive, with 15 Buy ratings and four Holds producing a “Moderate Buy” consensus; the average price target is $997.12, below the current share price.
• McKesson reported stronger-than-expected quarterly results, including $9.93 in EPS and $105.38 billion in revenue, up 7.7% year over year, while guiding to fiscal 2027 EPS of $44.20–$45.00.

McKesson Corporation (NYSE:MCK - Get Free Report)'s share price hit a new 52-week high during trading on Wednesday after Mizuho raised their price target on the stock from $905.00 to $1,020.00. Mizuho currently has a neutral rating on the stock. McKesson traded as high as $1,030.27 and last traded at $1,029.5240, with a volume of 789,379 shares. The stock had previously closed at $1,010.43.

A number of other research firms have also recently issued reports on MCK. Robert W. Baird set a $1,015.00 price objective on McKesson in a report on Thursday, August 6th. Barclays boosted their target price on shares of McKesson from $925.00 to $1,000.00 and gave the company an "overweight" rating in a research note on Wednesday, August 19th. Argus upped their price target on shares of McKesson from $850.00 to $970.00 and gave the stock a "buy" rating in a report on Thursday, September 3rd. Wells Fargo & Company raised their price target on shares of McKesson from $812.00 to $933.00 and gave the stock an "equal weight" rating in a research note on Tuesday, August 11th. Finally, Leerink Partners lifted their price objective on shares of McKesson from $1,030.00 to $1,070.00 and gave the company an "outperform" rating in a report on Wednesday, October 7th. Fifteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $997.12.

Insiders Place Their Bets

In other news, Director Bradley E. Lerman sold 301 shares of the firm's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $892.33, for a total transaction of $268,591.33. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Francisco Fraga sold 800 shares of McKesson stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $995.80, for a total value of $796,640.00. Following the completion of the sale, the executive vice president owned 5,423 shares of the company's stock, valued at $5,400,223.40. The trade was a 12.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 1,212 shares of company stock worth $1,164,182. 0.06% of the stock is currently owned by company insiders.

Trending Headlines about McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: UBS raised its price target to $1,200, implying additional upside and reinforcing the bullish view on McKesson’s pharmaceutical distribution and healthcare-services businesses. UBS raises target for McKesson stock
• Positive Sentiment: Leerink raised its target from $1,030 to $1,070, adding to a series of upward revisions from analysts. Leerink raises McKesson price target
• Positive Sentiment: McKesson recently reported quarterly earnings and revenue above consensus estimates. EPS was $9.93 versus $9.56 expected, while revenue reached $105.38 billion, up 7.7% year over year. Management’s fiscal 2027 EPS guidance of $44.20–$45.00 also supports the growth narrative. McKesson outperforms broader market
• Neutral Sentiment: Mizuho lifted its price target from $905 to $1,020 but maintained a “neutral” rating. The revised target is close to, but below, the current market valuation, suggesting limited near-term upside in that analyst’s view. Mizuho adjusts McKesson price target
• Negative Sentiment: Executive Vice President Francisco Fraga sold 800 shares worth approximately $796,640. However, the transaction was conducted under a pre-arranged Rule 10b5-1 plan, reducing its significance as a discretionary bearish signal. McKesson executive stock sale

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MCK. BlackRock Inc. acquired a new stake in shares of McKesson in the second quarter valued at about $8,156,743,000. Bank of America Corp DE lifted its stake in shares of McKesson by 2.4% in the first quarter. Bank of America Corp DE now owns 1,538,726 shares of the company's stock worth $1,331,552,000 after buying an additional 35,916 shares in the last quarter. Swedbank AB boosted its position in McKesson by 13.5% during the first quarter. Swedbank AB now owns 1,005,610 shares of the company's stock worth $870,215,000 after acquiring an additional 119,327 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in McKesson by 3.3% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 922,573 shares of the company's stock worth $697,096,000 after acquiring an additional 29,747 shares during the last quarter. Finally, Legal & General Group Plc purchased a new stake in McKesson during the 2nd quarter valued at about $656,566,000. 85.07% of the stock is currently owned by institutional investors.

McKesson Stock Performance

The company has a market cap of $120.03 billion, a PE ratio of 24.75, a PEG ratio of 2.01 and a beta of 0.30. The firm's 50 day moving average is $902.90 and its 200-day moving average is $839.47.

McKesson (NYSE:MCK - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $9.93 EPS for the quarter, beating analysts' consensus estimates of $9.56 by $0.37. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. The company had revenue of $105.38 billion during the quarter, compared to the consensus estimate of $103.88 billion. During the same quarter in the prior year, the firm earned $8.26 EPS. McKesson's quarterly revenue was up 7.7% on a year-over-year basis. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. On average, analysts predict that McKesson Corporation will post 44.71 EPS for the current year.

About McKesson

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson's principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.